Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Payables (2016 - 2025)

Fortress Biotech has reported Payables over the past 13 years, most recently at $47.1 million for Q4 2025.

  • Quarterly results put Payables at $47.1 million for Q4 2025, down 28.05% from a year ago — trailing twelve months through Dec 2025 was $47.1 million (down 28.05% YoY), and the annual figure for FY2025 was $47.1 million, down 28.05%.
  • Payables for Q4 2025 was $47.1 million at Fortress Biotech, up from $45.2 million in the prior quarter.
  • Over the last five years, Payables for FBIO hit a ceiling of $108.4 million in Q1 2023 and a floor of $10.5 million in Q3 2021.
  • Median Payables over the past 5 years was $71.2 million (2023), compared with a mean of $71.5 million.
  • Biggest five-year swings in Payables: tumbled 87.46% in 2021 and later surged 791.46% in 2022.
  • Fortress Biotech's Payables stood at $91.5 million in 2021, then grew by 9.75% to $100.4 million in 2022, then fell by 26.73% to $73.6 million in 2023, then decreased by 10.96% to $65.5 million in 2024, then fell by 28.05% to $47.1 million in 2025.
  • The last three reported values for Payables were $47.1 million (Q4 2025), $45.2 million (Q3 2025), and $48.6 million (Q2 2025) per Business Quant data.